Download PDF
Pneumologie 2007; 61(9): 590-594
DOI: 10.1055/s-2007-980121
Serie: Tabakprävention
© Georg Thieme Verlag Stuttgart · New York

Tabakrauchen, chronisch obstruktive Lungenerkrankung und Lungenkarzinom

Smoking, Chronic Obstructive Pulmonary Disease and Lung CancerS.  Andreas1 , F.  J. F.  Herth2 , A.  Rittmeyer1 , T.  Kyriss3 , T.  Raupach4
  • 1Lungenfachklinik Immenhausen
  • 2Thoraxklinik am Universitätsklinikum Heidelberg
  • 3Abteilung für Thoraxchirurgie, Klinik Schillerhöhe
  • 4Abteilung Kardiologie und Pneumologie, Georg-August-Universität, Göttingen
Further Information

Publication History

Publication Date:
30 August 2007 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Rauchen ist der wesentliche Risikofaktor für das Auftreten der chronisch-obstruktiven Lungenerkrankung (COPD) sowie des Lungenkarzinoms. Als chronische Erkrankung ist die COPD mit erheblicher Einschränkung der Lebensqualität verbunden. Das Lungenkarzinom stellt in Deutschland bei Männern die führende und bei Frauen die dritthäufigste Krebs-Todesursache dar. Die vorliegende Übersicht vermittelt Daten zur Primärprävention beider Erkrankungen und die positiven Effekte der Tabakentwöhnung auf den Verlauf bei bestehender Diagnose. Tabakrauch führt über oxidativen Stress zu einer chronischen Entzündung, die im Mittelpunkt der Pathogenese der COPD steht. Onkogene Mutationen sowie durch Tabakrauch abgeschaltete Tumor-Suppressorgenen führen zur Entstehung eines Lungenkarzinoms. Frauen tragen im Vergleich zu Männern bei gleicher Exposition ein höheres Risiko für die Entwicklung beider Erkrankungen. Die Tabakentwöhnung ist die einzige therapeutische Maßnahme, die bei Patienten mit COPD die Exazerbationen sowie die Mortalität reduziert und zu einer nachhaltigen Besserung der Lungenfunktion führt. Aufgrund des hohen Abhängigkeitsgrades von Rauchern mit COPD müssen bei der Entwöhnung dieser Patienten multimodale Konzepte mit Pharmakotherapie und psychosozialer Intervention verfolgt werden. Bei Patienten mit Lungenkarzinom sind positive Effekte des Rauchstopps auf Körpergewicht, Performancestatus, postoperative Komplikationen und Mortalität gesichert. Entsprechend sollte die Tabakentwöhnung integraler Bestandteil der Lungenkarzinom-Therapie sein. Weitere Untersuchungen sind allerdings notwendig, um die Tabakentwöhnung in Relation zu etablierten Therapieansätzen besser einzuordnen.

Abstract

Smoking is the main risk factor for chronic obstructive pulmonary disease (COPD) and lung cancer. Being a chronic disease, COPD severely impairs the quality of life. Lung cancer is the leading cause of death among German males and the third most important cause of death among German females. This review gives data on the primary prevention of both diseases and the beneficial effects of smoking cessation following disease manifestation. Smoking-induced oxidative stress triggers a chronic inflammation which is central to the pathogenesis of COPD. Smoking causes lung cancer by oncogenic mutations as well as inhibition of tumour-supressor genes. Women have an increased risk to develop COPD and lung cancer as compared to men when exposed to the same amounts of tobacco smoke. Smoking cessation is the only treatment capable of reducing exacerbations and mortality as well as sustainedly improving lung function. The high level of nicotine dependence in COPD patients mandates an intensive smoking cessation treatment including pharmacotherapy and psychosocial intervention. In patients with lung cancer, smoking cessation has confirmed favourable effects on body weight, performance status, postoperative complications and mortality. Thus, smoking cessation should be an integral part of lung cancer treatment. Further research is needed to better delineate the effects of smoking cessation in relation to other treatment modalities.

Literatur

  • 1 Consortium A. Tobacco or health in the European Union.  European Commission. 2004;  ISBN 92-894-8219-2 p. 1-295
    Google Scholar
  • 2 Godtfredsen N S, Vestbo J, Osler M. et al . Risk of hospital admission for COPD following smoking cessation and reduction: a Danish population study.  Thorax. 2002;  57 967-972
    Google Scholar
  • 3 Meyer P A, Mannino D M, Redd S C. et al . Characteristics of adults dying with COPD.  Chest. 2002;  122 2003-2008
    Google Scholar
  • 4 Calverley P M, Anderson J A, Celli B. et al . Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.  N Engl J Med. 2007;  356 775-789
    Google Scholar
  • 5 Shahab L, Jarvis M J, Britton J. et al . Prevalence, diagnosis and relation to tobacco dependence of chronic obstructive pulmonary disease in a nationally representative population sample.  Thorax. 2006;  61 1043-1047
    Google Scholar
  • 6 Wedzicha J A, Donaldson G C. Exacerbations of chronic obstructive pulmonary disease.  Respir Care. 2003;  48 1204-1213 discussion: 1213-1215
    Google Scholar
  • 7 Lundback B, Lindberg A, Lindstrom M. et al . Not 15 but 50 % of smokers develop COPD? - Report from the Obstructive Lung Disease in Northern Sweden Studies.  Respir Med. 2003;  97 115-122
    Google Scholar
  • 8 de Marco R, Accordini S, Cerveri I. et al . An international survey of chronic obstructive pulmonary disease in young adults according to GOLD stages.  Thorax. 2004;  59 120-125
    Google Scholar
  • 9 Ben-Zaken Cohen S, Pare P D, Man S FP. et al . The Growing Burden of Chronic Obstructive Pulmonary Disease and Lung Cancer in Women: Examining Sex Differences in Cigarette Smoke Metabolism. 10.1164/rccm.200611 - 1655PP.  Am J Respir Crit Care Med. 2007;  176 113-120
    Google Scholar
  • 10 Society E R. Lifting the smoke screen - 10 reasons for a smoke free Europe. Brussels: European Respiratory Society: B-1000 2006: p. 28ff
    Google Scholar
  • 11 Jaakkola M S, Jaakkola J J. Impact of smoke-free workplace legislation on exposures and health: possibilities for prevention.  Eur Respir J. 2006;  28 397-408
    Google Scholar
  • 12 Kerstjens H A, Rijcken B, Schouten J P. et al . Decline of FEV1 by age and smoking status: facts, figures, and fallacies.  Thorax. 1997;  52 820-827
    Google Scholar
  • 13 Gold D R, Wang X, Wypij D. et al . Effects of cigarette smoking on lung function in adolescent boys and girls.  N Engl J Med. 1996;  335 931-937
    Google Scholar
  • 14 Sherrill D L, Lebowitz M D, Knudson R J. et al . Smoking and symptom effects on the curves of lung function growth and decline.  Am Rev Respir Dis. 1991;  144 17-22
    Google Scholar
  • 15 Fletcher C, Peto R. The natural history of chronic airflow obstruction.  Br Med J. 1977;  1 1645-1648
    Google Scholar
  • 16 Tashkin D P, Detels R, Simmons M. et al . The UCLA population studies of chronic obstructive respiratory disease: XI. Impact of air pollution and smoking on annual change in forced expiratory volume in one second.  Am J Respir Crit Care Med. 1994;  149 1209-1217
    Google Scholar
  • 17 Kemeny D M, Vyas B, Vukmanovic-Stejic M. et al . CD8(+) T cell subsets and chronic obstructive pulmonary disease.  Am J Respir Crit Care Med. 1999;  160 S33-37
    Google Scholar
  • 18 Stanescu D, Sanna A, Veriter C. et al . Airways obstruction, chronic expectoration, and rapid decline of FEV1 in smokers are associated with increased levels of sputum neutrophils.  Thorax. 1996;  51 267-271
    Google Scholar
  • 19 Hautamaki R D, Kobayashi D K, Senior R M. et al . Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice.  Science. 1997;  277 2002-2004
    Google Scholar
  • 20 Marui N, Offermann M K, Swerlick R. et al . Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells.  J Clin Invest. 1993;  92 1866-1874
    Google Scholar
  • 21 Shapiro S D. The pathogenesis of emphysema: the elastase:antielastase hypothesis 30 years later.  Proc Assoc Am Physicians. 1995;  107 346-352
    Google Scholar
  • 22 Anthonisen N R, Connett J E, Kiley J P. et al . Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study.  Jama. 1994;  272 1497-1505
    Google Scholar
  • 23 Molfino N A. Genetics of COPD.  Chest. 2004;  125 1929-1940
    Google Scholar
  • 24 He J Q, Ruan J, Connett J E. et al . Antioxidant gene polymorphisms and susceptibility to a rapid decline in lung function in smokers.  Am J Respir Crit Care Med. 2002;  166 323-328
    Google Scholar
  • 25 Hogg J C. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease.  Lancet. 2004;  364 709-721
    Google Scholar
  • 26 Barnes P J, Shapiro S D, Pauwels R A. Chronic obstructive pulmonary disease: molecular and cellular mechanisms.  Eur Respir J. 2003;  22 672-688
    Google Scholar
  • 27 Wouters E F. Chronic obstructive pulmonary disease. 5: systemic effects of COPD.  Thorax. 2002;  57 1067-1070
    Google Scholar
  • 28 Reid M B. COPD as a muscle disease.  Am J Respir Crit Care Med. 2001;  164 1101-1102
    Google Scholar
  • 29 Andreas S, Anker S D, Scanlon P D. et al . Neurohumoral activation as a link to systemic manifestation of chronic lung disease.  Chest. 2005;  128 3618-3624
    Google Scholar
  • 30 Narkiewicz K, Borne P J van de, Hausberg M. et al . Cigarette smoking increases sympathetic outflow in humans.  Circulation. 1998;  98 528-534
    Google Scholar
  • 31 Scanlon P D, Connett J E, Waller L A. et al . Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study.  Am J Respir Crit Care Med. 2000;  161 381-390
    Google Scholar
  • 32 Willemse B W, Postma D S, Timens W. et al . The impact of smoking cessation on respiratory symptoms, lung function, airway hyperresponsiveness and inflammation.  Eur Respir J. 2004;  23 464-476
    Google Scholar
  • 33 Anthonisen N R, Skeans M A, Wise R A. et al . The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial.  Ann Intern Med. 2005;  142 233-239
    Google Scholar
  • 34 Raupach T, Nowak D, Hering T. et al . Smoking and pulmonary diseases, positive effects of smoking cessation.  Pneumologie. 2007;  61 11-14
    Google Scholar
  • 35 Meer R M van der, Wagena E J, Ostelo R WJG. et al .Smoking cessation for chronic obstructive pulmonary disease (Cochrane Review). In The Cochrane Library. Ltd.: Chichester, UK: John Wiley & Sons 2004
    Google Scholar
  • 36 Tashkin D, Kanner R, Bailey W. et al . Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial.  Lancet. 2001;  357 1571-1575
    Google Scholar
  • 37 Wagena E J, Zeegers M P, Schayck C P van. et al . Benefits and risks of pharmacological smoking cessation therapies in chronic obstructive pulmonary disease.  Drug Saf. 2003;  26 381-403
    Google Scholar
  • 38 Simmons M S, Connett J E, Nides M A. et al . Smoking reduction and the rate of decline in FEV(1): results from the Lung Health Study.  Eur Respir J. 2005;  25 1011-1017
    Google Scholar
  • 39 Lacasse Y, LaForge J, Maltais F. Got a match? Home oxygen therapy in current smokers.  Thorax. 2006;  61 374-375
    Google Scholar
  • 40 Weißbuch Lunge 2005, ed. N. Konietzko .Stuttgart: Georg Thieme Verlag 2005
  • 41 Parrott S, Godfrey C, Raw M. et al . Guidance for commissioners on the cost effectiveness of smoking cessation interventions. Health Educational Authority.  Thorax. 1998;  53 Suppl 5 Pt 2 S1-38
    Google Scholar
  • 42 Peto R, Darby S, Deo H. et al . Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies.  Bmj. 2000;  321 323-329
    Google Scholar
  • 43 The Health Consequences of Smoking: A Report of the Surgeon General. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion. Atlanta, GA: Office on Smoking and Health 2004
    Google Scholar
  • 44 Zhou W, Heist R S, Liu G. et al . Smoking cessation before diagnosis and survival in early stage non-small cell lung cancer patients.  Lung Cancer. 2006;  53 375-380
    Google Scholar
  • 45 Tsao A S, Liu D, Lee J J. et al . Smoking affects treatment outcome in patients with advanced nonsmall cell lung cancer.  Cancer. 2006;  106 2428-2436
    Google Scholar
  • 46 Thomas L, Doyle L A, Edelman M J. Lung cancer in women: emerging differences in epidemiology, biology, and therapy.  Chest. 2005;  128 370-381
    Google Scholar
  • 47 Keil U, Becher H, Heidrich J. et al .Passivrauchbedingte Morbidität und Mortalität in Deutschland. In: Passivrauchen - ein unterschätztes Gesundheitsrisiko. Heidelberg: Deutsches Krebsforschungszentrum 2005
    Google Scholar
  • 48 Hackshaw A K, Law M R, Wald N J. The accumulated evidence on lung cancer and environmental tobacco smoke.  Bmj. 1997;  315 980-988
    Google Scholar
  • 49 Tokuhata G K, Lilienfeld A M. Familial aggregation of lung cancer in humans.  J Natl Cancer Inst. 1963;  30 289-312
    Google Scholar
  • 50 Sanderson Cox L, Patten C A, Ebbert J O. et al . Tobacco use outcomes among patients with lung cancer treated for nicotine dependence.  J Clin Oncol. 2002;  20 3461-3469
    Google Scholar
  • 51 Dresler C M. Is it more important to quit smoking than which chemotherapy is used?.  Lung Cancer. 2003;  39 119-124
    Google Scholar
  • 52 Gritz E R, Dresler C, Sarna L. Smoking, the missing drug interaction in clinical trials: ignoring the obvious.  Cancer Epidemiol Biomarkers Prev. 2005;  14 2287-2293
    Google Scholar
  • 53 Vaporciyan A A, Merriman K W, Ece F. et al . Incidence of major pulmonary morbidity after pneumonectomy: association with timing of smoking cessation.  Ann Thorac Surg. 2002;  73 420-425; discussion: 425 - 426
    Google Scholar
  • 54 Moller A M, Pedersen T, Villebro N. et al . A study of the impact of long-term tobacco smoking on postoperative intensive care admission.  Anaesthesia. 2003;  58 55-59
    Google Scholar
  • 55 Moller A M, Villebro N, Pedersen T. et al . Effect of preoperative smoking intervention on postoperative complications: a randomised clinical trial.  Lancet. 2002;  359 114-117
    Google Scholar
  • 56 Baser S, Shannon V R, Eapen G A. et al . Smoking cessation after diagnosis of lung cancer is associated with a beneficial effect on performance status.  Chest. 2006;  130 1784-1790
    Google Scholar
  • 57 Tammemagi C M, Neslund-Dudas C, Simoff M. et al . In lung cancer patients, age, race-ethnicity, gender and smoking predict adverse comorbidity, which in turn predicts treatment and survival.  J Clin Epidemiol. 2004;  57 597-609
    Google Scholar
  • 58 Toh C K, Wong E H, Lim W T. et al . The impact of smoking status on the behavior and survival outcome of patients with advanced non-small cell lung cancer: a retrospective analysis.  Chest. 2004;  126 1750-1756
    Google Scholar
  • 59 Hamilton M, Wolf J L, Rusk J, Beard S E. et al . Effects of smoking on the pharmacokinetics of erlotinib.  Clin Cancer Res. 2006;  12 2166-2171
    Google Scholar
  • 60 Buccheri G, Ferrigno D. Importance of weight loss definition in the prognostic evaluation of non-small-cell lung cancer.  Lung Cancer. 2001;  34 433-440
    Google Scholar
  • 61 Issell B F, Valdivieso M, Hersh E M. et al . Combination chemoimmunotherapy for extensive non-oat cell lung cancer.  Cancer Treat Rep. 1978;  62 1059-1063
    Google Scholar
  • 62 Matthews N E, Adams M A, Maxwell L R. et al . Nitric oxide-mediated regulation of chemosensitivity in cancer cells.  J Natl Cancer Inst. 2001;  93 1879-1885
    Google Scholar
  • 63 Dasgupta P, Kinkade R, Joshi B. et al . Nicotine inhibits apoptosis induced by chemotherapeutic drugs by up-regulating XIAP and survivin.  Proc Natl Acad Sci USA. 2006;  103 6332-6337
    Google Scholar
  • 64 Fox J L, Rosenzweig K E, Ostroff J S. The effect of smoking status on survival following radiation therapy for non-small cell lung cancer.  Lung Cancer. 2004;  44 287-293
    Google Scholar
  • 65 Videtic G M, Stitt L W, Dar A R. et al . Continued cigarette smoking by patients receiving concurrent chemoradiotherapy for limited-stage small-cell lung cancer is associated with decreased survival.  J Clin Oncol. 2003;  21 1544-1549
    Google Scholar
  • 66 Sarihan S, Ercan I, Saran A. et al . Evaluation of infections in non-small cell lung cancer patients treated with radiotherapy.  Cancer Detect Prev. 2005;  29 181-188
    Google Scholar
  • 67 Monson J M, Stark P, Reilly J J. et al . Clinical radiation pneumonitis and radiographic changes after thoracic radiation therapy for lung carcinoma.  Cancer. 1998;  82 842-850
    Google Scholar
  • 68 Mehta V. Radiation pneumonitis and pulmonary fibrosis in non-small-cell lung cancer: pulmonary function, prediction, and prevention.  Int J Radiat Oncol Biol Phys. 2005;  63 5-24
    Google Scholar
  • 69 Tucker M A, Murray N, Shaw E G. et al . Second primary cancers related to smoking and treatment of small-cell lung cancer. Lung Cancer Working Cadre.  J Natl Cancer Inst. 1997;  89 1782-1788
    Google Scholar
  • 70 Richardson G E, Tucker M A, Venzon D J. et al . Smoking cessation after successful treatment of small-cell lung cancer is associated with fewer smoking-related second primary cancers.  Ann Intern Med. 1993;  119 383-390
    Google Scholar
  • 71 Ruff L K, Volmer T, Nowak D. et al . The economic impact of smoking in Germany.  Eur Respir J. 2000;  16 385-390
    Google Scholar

Prof. Dr. med. Stefan Andreas

Lungenfachklinik Immenhausen

Robert-Koch-Straße 3

34376 Immenhausen

Email: sandreas@lungenfachklinik-immenhausen.de

      >